|Awarded On||November 16, 2016|
|Title||Palbociclib synergizes with autophagy inhibitors to induce senescence in breast cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Khandan Keyomarsi|
Newer strategies are needed for the treatment of advanced hormone receptor-positive/HER2-negative breast cancer; the subtype associated with the greatest number of cancer deaths. While agents such as mTOR and CDK 4/6 blockade can delay progression when added to hormonal therapy, no improvement in survival has been observed. Virtually all patients eventually exhibit progression and about one third never respond, or progress within less than 4-6 months. The use of the approved CDK 4/6 inhibitor, palbociclib (PD), also results in neutropenia, necessitating treatment delay or discontinuation. Also, there are no predictive biomarkers to identify tumors with intrinsic and/or acquired resistan...